메글루민 안티모니에이트

용도

• Leishmaniosis (off-label)
• Leishmaniasis (First line treatment)
• Leishmaniasis
• Leishmaniasis
• Leishmaniosis

투여 방법

가능한 부작용

• Injection site reactions (cutaneous abscesses, cellulitis, pain)
• Lethargy
• Gastrointestinal effects (inappetence, vomiting)
• Transient increases in liver enzymes
• Nephrotoxicity (tubular damage, proximal tubule cell vacuolization, coagulative necrosis)
• Pain and swelling at the injection site
• Nephrotoxicity (proteinuria, elevated BUN/creatinine)
• Anorexia
• Vomiting
• Hepatotoxicity (rare)
• Myalgia/arthralgia

주의사항 및 금기

• Previous hypersensitivity to meglumine antimoniate
• Severe renal, hepatic, or cardiac failure (relative contraindication; weigh risks vs. benefits)
• Severe renal impairment
• Hepatic failure
• Cardiac disease
• **Extreme caution** is advised in patients with pre-existing **renal, hepatic, or cardiac insufficiency**. * **Renal Impairment**: Decreased renal function can lead to significant drug accumulation and an increased risk of severe toxicity. In dogs with severe renal failure (IRIS stages III-IV), correction of fluid and acid-base imbalances prior to treatment with allopurinol alone is recommended before considering antimonials. * **Hypersensitivity**: Hypersensitivity reactions have been reported in humans; avoid in patients with known allergies to the drug. * **Pregnancy**: Teratogenic effects (fetal resorptions, bone abnormalities) have been noted in animal models. Weigh risks versus benefits carefully.

약물 상호작용

• Agents that can prolong QT interval (e.g., tricyclic antidepressants, disopyramide, quinidine, procainamide): Meglumine antimoniate may prolong QT interval further with increased risk for arrhythmias
• Aminoglycosides: Increased risk of nephrotoxicity
• NSAIDs: Increased risk of nephrotoxicity

자주 묻는 질문